Similarly, a humanized BsAbs with dual binding sites targeting both CD3 expressed on T cells and BCMA on myeloma cells, Teclistamab (cqyv, JNJ64007957) has proven highly active as a single agent with a deep and durable response. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.